tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Liver Diseases D008107 31 associated lipids
Long QT Syndrome D008133 10 associated lipids
Lung Abscess D008169 1 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lymphocele D008210 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Lymphoma D008223 18 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Malacoplakia D008287 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Mastocytosis D008415 5 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Mediastinitis D008480 2 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Meningococcal Infections D008589 3 associated lipids
Meningoencephalitis D008590 4 associated lipids
Metaplasia D008679 7 associated lipids
Mite Infestations D008924 1 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Mouth Diseases D009059 5 associated lipids
Moyamoya Disease D009072 1 associated lipids
Multiple Myeloma D009101 13 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Mutism D009155 1 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Mycoses D009181 18 associated lipids
Myelitis D009187 1 associated lipids
Myxedema D009230 2 associated lipids
Nail Diseases D009260 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nephritis D009393 19 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Carcas-Sansuán AJ Limited sampling strategies for once daily tacrolimus exposure monitoring. 2016 Eur. J. Clin. Pharmacol. pmid:26939899
Herz S et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. 2016 Eur. J. Cancer pmid:27614165
Hazama Y et al. Effect of Physiological Changes in the Skin on Systemic Absorption of Tacrolimus Following Topical Application in Rats. 2016 Biol. Pharm. Bull. pmid:26934927
Nakajima A et al. Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis. 2016 Mod Rheumatol pmid:26934454
Iguchi A et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation. 2016 Pediatr Transplant pmid:26526424
Fukuta T et al. Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity. 2016 Sci Rep pmid:27440054
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Lim SW et al. Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus. 2016 Sci Rep pmid:27436514
Knight SR Intrapatient variability in tacrolimus exposure - a useful tool for clinical practice? 2016 Transpl. Int. pmid:27283231
Shuker N et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. 2016 Transpl. Int. pmid:27188932
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Nie F et al. [Post-transplant kidney from C-III donation after cardiac death of children: a clinicopathologic study of 20 cases]. 2016 Zhonghua Bing Li Xue Za Zhi pmid:26879429
Song JL et al. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation. 2016 World J. Gastroenterol. pmid:26877618
Than NN et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. 2016 Scand. J. Gastroenterol. pmid:26458216
Dharnidharka VR et al. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. 2016 Transpl. Int. pmid:27564782
Rostaing L et al. Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases. 2016 Ther Apher Dial pmid:27073167
Malik N et al. A simple office-based procedure for patients with extensive vitiligo. 2016 J. Am. Acad. Dermatol. pmid:27745651
Lee JH et al. Stability of tacrolimus solutions in polyolefin containers. 2016 Am J Health Syst Pharm pmid:26796907
Ward I et al. Digital Pulp Ulcerations and Inverse Gottron Papules in Melanoma Differentiation-Associated Gene 5-Related Dermatomyositis. 2016 J Clin Rheumatol pmid:27464773
Armand P et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. 2016 Br. J. Haematol. pmid:26729448
Hanaoka K et al. A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy. 2016 Transpl. Immunol. pmid:27545900
Matsa E et al. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. 2016 Cell Stem Cell pmid:27545504
Lee B et al. Appropriate timing of tacrolimus concentration measurements in the emergency department. 2016 Am J Health Syst Pharm pmid:27543574
Mokuda S and Oiwa H Successful treatment of FKBP51-expressed multicentric reticulohistiocytosis using combination therapy with low-dose denosumab and tacrolimus. 2016 Scand. J. Rheumatol. pmid:26652057
Komaki Y et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. 2016 J Crohns Colitis pmid:26645641
Vadcharavivad S et al. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. 2016 J Clin Pharm Ther pmid:27191538
Ikeya K et al. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. 2016 J Crohns Colitis pmid:26581895
Milgrom SA et al. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. 2016 J Med Case Rep pmid:27465468
Pouché L et al. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. 2016 Pharmacogenomics pmid:26799749
Shao K et al. Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation. 2016 Scand. J. Immunol. pmid:26524694
Cena T et al. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients. 2016 Transpl. Int. pmid:27343849
Yeo L and Ormerod AD Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus. 2016 Clin. Exp. Dermatol. pmid:27339859
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Chacon A and Mercer J Successful management of angiolymphoid hyperplasia with eosinophilia in a split-face trial of topical tacrolimus and timolol solution. 2016 G Ital Dermatol Venereol pmid:25014586
Grześk E et al. Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smooth muscle cells. 2016 Pharmacol Rep pmid:26721374
Riegersperger M et al. The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. 2016 Clin. Lab. pmid:28164520
Fernández de Castillo Torras L et al. Treatment with ulipristal acetate (Esmya(®)) and plasma levels of tacrolimus: a case report. 2016 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:27282803
Levitsky J et al. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. 2016 PLoS ONE pmid:27275747
Serrano-Mollar A et al. Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis. 2016 Chest pmid:27020420
Seok J et al. Recalcitrant steroid-induced rosacea successfully treated with 0.03% tacrolimus and 595-nm pulsed dye laser. 2016 Eur J Dermatol pmid:27193042
Sisti A et al. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. 2016 An Bras Dermatol pmid:27192518
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Baraldo M Meltdose Tacrolimus Pharmacokinetics. 2016 Transplant. Proc. pmid:27109969
Felix MJ et al. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. 2016 Pharmacotherapy pmid:26799522
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Shimizu K et al. Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its antiallergic effect. 2016 J Drug Target pmid:27030163
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Ha DH et al. Potential differentiation ability of gingiva originated human mesenchymal stem cell in the presence of tacrolimus. 2016 Sci Rep pmid:27721434
Taşoğlu Ö et al. Pregabalin: A New Adjunct in Calcineurin Inhibitor Pain Syndrome Treatment. 2016 Prog Transplant pmid:27312682